Center of Experimental Orthopaedics, Saarland University, Kirrberger Strasse 100, Building 37, 66421, Homburg, Germany.
Department of Orthopaedic Surgery, Saarland University Medical Center, Kirrberger Strasse 100, Building 37, 66421, Homburg, Germany.
Knee Surg Sports Traumatol Arthrosc. 2020 Mar;28(3):670-706. doi: 10.1007/s00167-019-05359-9. Epub 2019 Jan 18.
To systematically review and evaluate novel clinical data following microfracture treatment of knee articular cartilage defects.
A systematic review was performed by searching PubMed, ScienceDirect, and Cochrane Library databases for clinical trials on microfracture treatment, published between 2013 and 2018. Titles, abstracts, and articles were reviewed, and data concerning patient demographics, study design, pre-, intra-, and postoperative findings were extracted. PRISMA guidelines were applied. The methodological quality of the included studies was analyzed by the modified Coleman Methodology Score (CMS), and aggregate data were generated.
Eighteen studies including 1830 defects (1759 patients) were included. Of them, 8 (59% of patients) were cohort studies without a comparison group. Overall study quality was moderate (mean total CMS: 64 points), mainly due to low patient numbers, short follow-up periods, lack of control groups and structural repair tissue evaluation, and inhomogeneity in outcome parameters. Microfracture treatment of full-thickness articular cartilage defects (3.4 ± 2.1 cm) was performed at 43.4 ± 68.0 months of symptom duration. Postoperative assessment at 79.5 ± 27.2 months revealed failure rates of 11-27% within 5 years and 6-32% at 10 years. Imaging analysis was conducted in 10 studies, second-look arthroscopies were reported twice (n = 205 patients) and revealed well integrated fibrocartilaginous repair tissue.
Microfracture provides good function and pain relief at the mid-term and clinically largely satisfying results thereafter. Standardized, high-quality future study designs will better refine optimal indications for microfracture in the context of cartilage repair strategies.
This systematic review is based on studies with levels of evidence ranging between I and IV (see results section and Table). Therefore, and according to this journals Instructions for Authors (SYSTEMATIC REVIEWS AND META-ANALYSES are assigned a level of evidence equivalent to the lowest level of evidence used from the manuscripts analysed), level of evidence is IV.
系统回顾和评估微骨折治疗膝关节软骨缺损的新临床数据。
通过检索 PubMed、ScienceDirect 和 Cochrane Library 数据库,对 2013 年至 2018 年期间发表的微骨折治疗的临床试验进行了系统回顾。查阅标题、摘要和文章,并提取有关患者人口统计学、研究设计、术前、术中和术后发现的数据。应用 PRISMA 指南。采用改良的 Coleman 方法学评分(CMS)分析纳入研究的方法学质量,并生成汇总数据。
纳入 18 项研究,共 1830 个缺损(1759 例患者)。其中,8 项(59%的患者)为无对照组的队列研究。总体研究质量为中等(平均总 CMS:64 分),主要原因是患者数量少、随访时间短、缺乏对照组和结构修复组织评估以及结果参数的异质性。对全层关节软骨缺损(3.4±2.1cm)进行微骨折治疗,症状持续时间为 43.4±68.0 个月。术后 79.5±27.2 个月的评估显示,5 年内失败率为 11-27%,10 年内为 6-32%。10 项研究进行了影像学分析,2 次报道了二次关节镜检查(n=205 例),显示出良好的整合纤维软骨修复组织。
微骨折在中期提供了良好的功能和疼痛缓解,并在此后提供了临床上大多令人满意的结果。未来的标准化、高质量研究设计将更好地细化微骨折在软骨修复策略背景下的最佳适应证。
本系统评价基于证据水平在 I 至 IV 之间的研究(见结果部分和表)。因此,根据本杂志的作者指南(系统评价和荟萃分析被分配与分析的手稿中使用的最低证据水平相当的证据水平),证据水平为 IV。